Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.
<h4>Background</h4>Risk models (RM) need external validation to assess their value beyond the setting in which they were developed. We validated a RM combining mpMRI and clinical parameters for the probability of harboring significant prostate cancer (sPC, Gleason Score ≥ 3+4) for biopsy...
Main Authors: | Jan Philipp Radtke, Francesco Giganti, Manuel Wiesenfarth, Armando Stabile, Jose Marenco, Clement Orczyk, Veeru Kasivisvanathan, Joanne Nyaboe Nyarangi-Dix, Viktoria Schütz, Svenja Dieffenbacher, Magdalena Görtz, Albrecht Stenzinger, Wilfried Roth, Alex Freeman, Shonit Punwani, David Bonekamp, Heinz-Peter Schlemmer, Markus Hohenfellner, Mark Emberton, Caroline M Moore |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0221350 |
Similar Items
-
Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists
by: Francesco Giganti, et al.
Published: (2021-05-01) -
The value of PSA density in PI-RADS 3 lesions on multiparametric MRI - a strategy to avoid unnecessary prostate biopsies
by: M. Görtz, et al.
Published: (2020-07-01) -
Retzius-sparing robot-assisted laparoscopic radical prostatectomy: functional and early oncologic results in aggressive and locally advanced prostate cancer
by: Joanne Nyaboe Nyarangi-Dix, et al.
Published: (2019-11-01) -
A new quality control scoring system for multiparametric MRI of the prostate from the PRECISION trial
by: F. Giganti, et al.
Published: (2020-07-01) -
From screening to mortality reduction: An overview of the patient journey in ERSPC Rotterdam
by: M.J. Roobol, et al.
Published: (2020-07-01)